Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications
Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, n...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1065379/full |
| _version_ | 1797955964295446528 |
|---|---|
| author | Pei Du Guangqing Li Lu Wu Minger Huang |
| author_facet | Pei Du Guangqing Li Lu Wu Minger Huang |
| author_sort | Pei Du |
| collection | DOAJ |
| description | Cervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future. |
| first_indexed | 2024-04-10T23:42:33Z |
| format | Article |
| id | doaj.art-5f1efcd3eab8415cb4d466842a5c4dd3 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T23:42:33Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-5f1efcd3eab8415cb4d466842a5c4dd32023-01-11T06:20:22ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.10653791065379Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applicationsPei DuGuangqing LiLu WuMinger HuangCervical cancer is a public health problem of extensive clinical importance. Excision repair cross-complementation group 1 (ERCC1) was found to be a promising biomarker of cervical cancer over the years. At present, there is no relevant review article that summarizes such evidence. In this review, nineteen eligible studies were included for evaluation and data extraction. Based on the data from clinical and experimental studies, ERCC1 plays a key role in the progression of carcinoma of the uterine cervix and the therapeutic response of chemoradiotherapy. The majority of the included studies (13/19, 68%) suggested that ERCC1 played a pro-oncogenic role in both early-stage and advanced cervical cancer. High expression of ERCC1 was found to be associated with the poor survival rates of the patients. ERCC1 polymorphism analyses demonstrated that ERCC1 might be a useful tool for predicting the risk of cervical cancer and the treatment-related toxicities. Experimental studies indicated that the biological effects exerted by ERCC1 in cervical cancer might be mediated by its associated genes and affected signaling pathways (i.e., XPF, TUBB3, and. To move towards clinical applications by targeting ERCC1 in cervical cancer, more clinical, in-vitro, and in-vivo investigations are still warranted in the future.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1065379/fullercc1cervical cancercisplatinsurvivalmechanism |
| spellingShingle | Pei Du Guangqing Li Lu Wu Minger Huang Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications Frontiers in Immunology ercc1 cervical cancer cisplatin survival mechanism |
| title | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
| title_full | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
| title_fullStr | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
| title_full_unstemmed | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
| title_short | Perspectives of ERCC1 in early-stage and advanced cervical cancer: From experiments to clinical applications |
| title_sort | perspectives of ercc1 in early stage and advanced cervical cancer from experiments to clinical applications |
| topic | ercc1 cervical cancer cisplatin survival mechanism |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1065379/full |
| work_keys_str_mv | AT peidu perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT guangqingli perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT luwu perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications AT mingerhuang perspectivesofercc1inearlystageandadvancedcervicalcancerfromexperimentstoclinicalapplications |